E
ImmunoPrecise Antibodies Ltd.
IPA
$0.3918
-$0.0082-2.05%
E
Sell
9/6/2023Downgrade
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to E+ from D- on 9/6/2023 due to a decline in the volatility index and total return index.
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to E+ from D- on 9/6/2023 due to a decline in the volatility index and total return index.
D
Sell
8/16/2023Upgraded
ImmunoPrecise Antibodies Ltd. (IPA) was upgraded to D- from E+ on 8/16/2023 due to an increase in the volatility index and valuation index.
ImmunoPrecise Antibodies Ltd. (IPA) was upgraded to D- from E+ on 8/16/2023 due to an increase in the volatility index and valuation index.
E
Sell
8/1/2023Downgrade
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to E+ from D- on 8/1/2023 due to a decline in the volatility index, growth index and total return index.
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to E+ from D- on 8/1/2023 due to a decline in the volatility index, growth index and total return index.
D
Sell
7/11/2023Upgraded
ImmunoPrecise Antibodies Ltd. (IPA) was upgraded to D- from E+ on 7/11/2023 due to an increase in the volatility index.
ImmunoPrecise Antibodies Ltd. (IPA) was upgraded to D- from E+ on 7/11/2023 due to an increase in the volatility index.
E
Sell
7/3/2023Downgrade
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to E+ from D- on 7/3/2023 due to a large decline in the total return index and volatility index.
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to E+ from D- on 7/3/2023 due to a large decline in the total return index and volatility index.
D
Sell
3/14/2023Downgrade
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/24/2023Downgrade
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to D from D+ on 2/24/2023 due to a decline in the total return index.
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to D from D+ on 2/24/2023 due to a decline in the total return index.
D
Sell
2/9/2023Upgraded
ImmunoPrecise Antibodies Ltd. (IPA) was upgraded to D+ from D- on 02/09/2023.
ImmunoPrecise Antibodies Ltd. (IPA) was upgraded to D+ from D- on 02/09/2023.
D
Sell
2/8/2023Downgrade
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to D- from D+ on 2/8/2023 due to a decline in the total return index.
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to D- from D+ on 2/8/2023 due to a decline in the total return index.
D
Sell
12/16/2022Upgraded
ImmunoPrecise Antibodies Ltd. (IPA) was upgraded to D+ from D on 12/16/2022 due to a noticeable increase in the growth index, volatility index and valuation index. Operating cash flow increased 64.94% from -$8.02M to -$2.81M, earnings per share increased from -$0.2947 to -$0.2221, and EBIT increased 24.5% from -$7.79M to -$5.88M.
ImmunoPrecise Antibodies Ltd. (IPA) was upgraded to D+ from D on 12/16/2022 due to a noticeable increase in the growth index, volatility index and valuation index. Operating cash flow increased 64.94% from -$8.02M to -$2.81M, earnings per share increased from -$0.2947 to -$0.2221, and EBIT increased 24.5% from -$7.79M to -$5.88M.
D
Sell
5/5/2022Upgraded
ImmunoPrecise Antibodies Ltd. (IPA) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index.
ImmunoPrecise Antibodies Ltd. (IPA) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index.
D
Sell
4/20/2022Downgrade
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 6.69 to 5.48.
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 6.69 to 5.48.
D
Sell
11/23/2021Upgraded
ImmunoPrecise Antibodies Ltd. (IPA) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
ImmunoPrecise Antibodies Ltd. (IPA) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
D
Sell
11/8/2021Downgrade
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to D- from D on 11/08/2021.
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to D- from D on 11/08/2021.
D
Sell
10/11/2021Downgrade
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to D from D+ on 10/11/2021 due to a decline in the total return index.
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to D from D+ on 10/11/2021 due to a decline in the total return index.
D
Sell
9/13/2021Upgraded
ImmunoPrecise Antibodies Ltd. (IPA) was upgraded to D+ from D on 9/13/2021 due to a significant increase in the solvency index, total return index and volatility index.
ImmunoPrecise Antibodies Ltd. (IPA) was upgraded to D+ from D on 9/13/2021 due to a significant increase in the solvency index, total return index and volatility index.
D
Sell
3/11/2020Upgraded
ImmunoPrecise Antibodies Ltd. (IPATF) was upgraded to D from D- on 3/11/2020 due to an increase in the growth index, efficiency index and total return index. Operating cash flow increased 97.29% from -$1.19M to -$32.1, EBIT increased 79.53% from -$773.8 to -$158.4, and earnings per share increased from -$0.0152 to -$0.007.
ImmunoPrecise Antibodies Ltd. (IPATF) was upgraded to D from D- on 3/11/2020 due to an increase in the growth index, efficiency index and total return index. Operating cash flow increased 97.29% from -$1.19M to -$32.1, EBIT increased 79.53% from -$773.8 to -$158.4, and earnings per share increased from -$0.0152 to -$0.007.
D
Sell
8/30/2019Downgrade
ImmunoPrecise Antibodies Ltd. (IPATF) was downgraded to D- from D on 8/30/2019 due to a noticeable decline in the efficiency index, total return index and solvency index. Net income declined 223.43% from -$891.9 to -$2.88M, the quick ratio declined from 3.32 to 1.03, and debt to equity increased from 0.14 to 0.16.
ImmunoPrecise Antibodies Ltd. (IPATF) was downgraded to D- from D on 8/30/2019 due to a noticeable decline in the efficiency index, total return index and solvency index. Net income declined 223.43% from -$891.9 to -$2.88M, the quick ratio declined from 3.32 to 1.03, and debt to equity increased from 0.14 to 0.16.
D
Sell
12/28/2018Upgraded
ImmunoPrecise Antibodies Ltd. (IPATF) was upgraded to D from D- on 12/28/2018 due to a noticeable increase in the total return index, efficiency index and volatility index. Total capital increased 41.85% from $12.55M to $17.8M.
ImmunoPrecise Antibodies Ltd. (IPATF) was upgraded to D from D- on 12/28/2018 due to a noticeable increase in the total return index, efficiency index and volatility index. Total capital increased 41.85% from $12.55M to $17.8M.
D
Sell
12/29/2017Upgraded
ImmunoPrecise Antibodies Ltd. (IPATF) was upgraded to D- from E+ on 12/29/2017 due to an increase in the valuation index, growth index and efficiency index. Total capital increased 316.22% from $1.97M to $8.21M, total revenue increased 135.28% from $447.5 to $1.05M, and operating cash flow increased 15.69% from -$906.8 to -$764.5.
ImmunoPrecise Antibodies Ltd. (IPATF) was upgraded to D- from E+ on 12/29/2017 due to an increase in the valuation index, growth index and efficiency index. Total capital increased 316.22% from $1.97M to $8.21M, total revenue increased 135.28% from $447.5 to $1.05M, and operating cash flow increased 15.69% from -$906.8 to -$764.5.
E
Sell
11/13/2017Downgrade
ImmunoPrecise Antibodies Ltd. (IPATF) was downgraded to E+ from D- on 11/13/2017 due to a noticeable decline in the volatility index and total return index.
ImmunoPrecise Antibodies Ltd. (IPATF) was downgraded to E+ from D- on 11/13/2017 due to a noticeable decline in the volatility index and total return index.
D
Sell
10/2/2017Upgraded
ImmunoPrecise Antibodies Ltd. (IPATF) was upgraded to D- from E on 10/2/2017 due to an increase in the volatility index, growth index and total return index. Total revenue increased 0.2% from $446.6 to $447.5.
ImmunoPrecise Antibodies Ltd. (IPATF) was upgraded to D- from E on 10/2/2017 due to an increase in the volatility index, growth index and total return index. Total revenue increased 0.2% from $446.6 to $447.5.
E
Sell
7/5/2017Upgraded
ImmunoPrecise Antibodies Ltd. (IPATF) was upgraded to E from E- on 7/5/2017 due to an increase in the dividend index.
ImmunoPrecise Antibodies Ltd. (IPATF) was upgraded to E from E- on 7/5/2017 due to an increase in the dividend index.
E
Sell
4/19/2017Downgrade
ImmunoPrecise Antibodies Ltd. (IPATF) was downgraded to E- from E on 4/19/2017 due to a decline in the volatility index.
ImmunoPrecise Antibodies Ltd. (IPATF) was downgraded to E- from E on 4/19/2017 due to a decline in the volatility index.
E
Sell
4/17/2017None
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to E from U on 04/17/2017.
ImmunoPrecise Antibodies Ltd. (IPA) was downgraded to E from U on 04/17/2017.
NASDAQ
03/07/2025 4:00PM Eastern
Quotes delayed
